Markets:

Overview

News

Currencies

International

Treasuries

Caribou Biosciences, Inc. - Common Stock (NQ:CRBU)

1.646 -0.054 (-3.18%)

Streaming Delayed Price Updated: 3:34 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Caribou Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today? ↗

November 03, 2025

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments ↗

November 03, 2025

Via Stocktwits

Expert Ratings For Caribou Biosciences ↗

September 03, 2024

Via Benzinga

Caribou Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

August 14, 2024

Via Benzinga

Evaluating Caribou Biosciences: Insights From 4 Financial Analysts ↗

July 17, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 03, 2025

Via Benzinga

Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket ↗

November 03, 2025

Via Benzinga

Caribou Biosciences Inc (NASDAQ:CRBU) Posts Mixed Q2 2025 Earnings with Revenue Beat but Wider Loss ↗

August 12, 2025

Caribou Biosciences reports Q2 2025 earnings with revenue beating estimates at $2.67M but a wider EPS loss of -$0.58. Clinical updates expected in H2 2025.

Via Chartmill

FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering ↗

June 20, 2025

FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Caribou Biosciences ↗

June 04, 2024

Via Benzinga

Expert Ratings For Caribou Biosciences ↗

May 16, 2024

Via Benzinga

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for...

Via MarketMinute

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 26, 2024

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 03, 2024

Via Benzinga

Attention Biotech Investors - Stocks To Watch ↗

May 16, 2024

RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming binary catalysts, McCarthy highlights Agios Pharmaceuticals, Caribou Biosciences,...

Via Benzinga

3 Underappreciated Stocks That Could 10x in 10 Years ↗

May 12, 2024

10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line.

Via InvestorPlace

CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

CRBU stock results show that Caribou Biosciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗

April 05, 2024

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday.

Via Benzinga

Topics Stocks

Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points ↗

March 13, 2024

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, but the index remained in the "Greed" zone on Tuesday.

Via Benzinga

Topics Economy Stocks

Gold Down Over 1%; ClearOne Shares Spike Higher ↗

March 12, 2024

U.S. stocks traded higher toward the end of trading, with the S&P 500 index gaining over 1% on Tuesday. The Dow traded up 0.74% to 39,057.10 while the NASDAQ rose 1.41% to 16,245.83. The S&P 500 also...

Via Benzinga

Topics Stocks

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

March 12, 2024

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 12, 2024

Via Benzinga

Why Caribou Biosciences Stock Is Crashing Today ↗

March 12, 2024

Investors didn't like the clinical-stage biotech's Q4 update for one key reason.

Via The Motley Fool

It's A Bull Market But Harder To Pick Small Cap Biotech Winners Because Of Volatility ↗

March 11, 2024

Biotech is in a bull market aș measured by 2023 trends with a double testing of lows on 11/23.

Via Talk Markets

Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold ↗

February 26, 2024

Buy this stock if you're daring, but avoid it for now if you aren't.

Via The Motley Fool

2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare ↗

February 12, 2024

It's less scary to take on risky investments when the market is rising.

Via The Motley Fool

3 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

January 15, 2024

These companies are still in the early innings of their growth potential.

Via The Motley Fool

3 Gene-Editing Stocks With the Potential to Mint Millionaires ↗

December 13, 2023

Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.